BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24764147)

  • 1. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics.
    Kim A; Chung I; Yoon SH; Yu KS; Lim KS; Cho JY; Lee H; Jang IJ; Chung JY
    Drug Metab Dispos; 2014 Jul; 42(7):1174-9. PubMed ID: 24764147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
    Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
    Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers.
    Liu G; Wen J; Guo D; Wang Z; Hu X; Tang J; Liu Z; Zhou H; Zhang W
    J Pharmacol Sci; 2016 Dec; 132(4):244-248. PubMed ID: 27245553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers.
    Noh YH; Lim HS; Jung JA; Jin SJ; Kim MJ; Kim YH; Park HJ; Bae KS
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):605-13. PubMed ID: 22762856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
    Nies AT; Hofmann U; Resch C; Schaeffeler E; Rius M; Schwab M
    PLoS One; 2011; 6(7):e22163. PubMed ID: 21779389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
    Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
    Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
    Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interactions between topiramate and pioglitazone and metformin.
    Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald D
    Epilepsy Res; 2014 Nov; 108(9):1519-32. PubMed ID: 25219351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
    Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
    J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
    Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
    Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.
    Flory J; Haynes K; Leonard CE; Hennessy S
    Br J Clin Pharmacol; 2015 Feb; 79(2):330-6. PubMed ID: 25199921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.
    Smolders EJ; Colbers A; de Kanter CTMM; Velthoven-Graafland K; Wolberink LT; van Ewijk-Beneken Kolmer N; Drenth JPH; Aarnoutse RE; Tack CJ; Burger DM
    Br J Clin Pharmacol; 2017 Oct; 83(10):2225-2234. PubMed ID: 28474741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics.
    Wen J; Zeng M; Liu Z; Zhou H; Xu H; Huang M; Zhang W
    J Pharmacol Sci; 2019 Jan; 139(1):37-41. PubMed ID: 30538075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
    Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.